Immunovant, Inc. (IMVT)

Immunovant Balance Sheet

Financials in millions USD. Fiscal year is April - March.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	635.37	376.53	493.82	400.15	100.57
Cash & Cash Equivalents	635.37	376.53	493.82	400.15	100.57
Cash Growth	68.74%	-23.75%	23.41%	297.87%	1339.81%
Receivables	5.34	0.7	12.23	0.6	0
Other Current Assets	25.07	27.1	6.89	8.26	8.51
Total Current Assets	665.77	404.33	512.93	409.01	109.08
Property, Plant & Equipment	0.6	1.51	2.63	3.48	0.07
Other Long-Term Assets	0	0	0	0	0.25
Total Long-Term Assets	0.6	1.51	2.63	3.48	0.31
Total Assets	666.37	405.84	515.56	412.49	109.39
Accounts Payable	7.17	1.7	18.8	2.43	4.38
Current Debt	0.14	1.17	1.15	1.18	0
Other Current Liabilities	41.3	40.42	24.58	15.16	10.94
Total Current Liabilities	48.61	43.3	44.52	18.77	15.32
Long-Term Debt	0	0.05	1.22	2.24	0
Total Long-Term Liabilities	0	0.05	1.22	2.24	0
Total Liabilities	48.61	43.34	45.74	21.01	15.32
Total Debt	0.14	1.22	2.36	3.42	0
Debt Growth	-88.69%	-48.39%	-30.82%	-	-
Retained Earnings	-825.68	-566.35	-355.39	-198.66	-91.23
Comprehensive Income	1.91	0.85	0.4	-0.3	-0.02
Shareholders' Equity	617.76	362.49	469.83	391.48	94.07
Net Cash / Debt	635.23	375.31	491.45	396.73	100.57
Net Cash / Debt Growth	69.25%	-23.63%	23.88%	294.48%	1339.81%
Net Cash Per Share	4.60	3.05	4.48	4.52	2.33
Working Capital	617.16	361.04	468.41	390.24	93.76
Book Value Per Share	4.47	2.94	4.28	4.46	2.18

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).